These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

982 related articles for article (PubMed ID: 34358296)

  • 1. Need for More Randomized Controlled Trials With Rigorous Methodology to Confirm That Ivermectin Is Not a Viable Option for the Treatment of Coronavirus Disease 2019.
    Banno M; Tsujimoto Y; Ishikane M
    Clin Infect Dis; 2022 Mar; 74(6):1121-1122. PubMed ID: 34358296
    [No Abstract]   [Full Text] [Related]  

  • 2. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19.
    Kow CS; Hasan SS
    Am J Ther; 2021 Aug; 28(5):e616-e619. PubMed ID: 34387564
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
    Formiga FR; Leblanc R; de Souza Rebouças J; Farias LP; de Oliveira RN; Pena L
    J Control Release; 2021 Jan; 329():758-761. PubMed ID: 33038449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Ivermectin in the Treatment of Coronavirus Disease 2019: A Trial Sequential Analysis Highlights the Requirement of Additional Randomized, Controlled Trials.
    Padhi S; Pati A; Panda AK
    Clin Infect Dis; 2022 Mar; 74(6):1120-1121. PubMed ID: 34357386
    [No Abstract]   [Full Text] [Related]  

  • 7. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
    Ahmed S; Karim MM; Ross AG; Hossain MS; Clemens JD; Sumiya MK; Phru CS; Rahman M; Zaman K; Somani J; Yasmin R; Hasnat MA; Kabir A; Aziz AB; Khan WA
    Int J Infect Dis; 2021 Feb; 103():214-216. PubMed ID: 33278625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Global Early Empirical Therapy Randomized Study Design for Ivermectin in SARS-CoV-2 Infection.
    Bhaskar E
    Am J Ther; 2021 May; 28(4):e522-e523. PubMed ID: 34117145
    [No Abstract]   [Full Text] [Related]  

  • 9. Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials.
    Zein AFMZ; Sulistiyana CS; Raffaelo WM; Pranata R
    Diabetes Metab Syndr; 2021; 15(4):102186. PubMed ID: 34237554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature.
    Chaudhry MW; Zubair SM; Zubairi ABS; Irfan M
    Adv Respir Med; 2021; 89(4):413-418. PubMed ID: 34494244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivermectin in COVID-19: What do we know?
    Pandey S; Pathak SK; Pandey A; Salunke AA; Chawla J; Sharma A; Sharma S; Thivari P; Ratna HVK
    Diabetes Metab Syndr; 2020; 14(6):1921-1922. PubMed ID: 33032231
    [No Abstract]   [Full Text] [Related]  

  • 13. Ivermectin as a potential treatment for COVID-19?
    Chosidow O; Bernigaud C; Guillemot D; Giraudeau B; Lespine A; Changeux JP; Bourhy H; Lecuit M; Amoura Z
    PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009446. PubMed ID: 34061842
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.
    Ravikirti ; Roy R; Pattadar C; Raj R; Agarwal N; Biswas B; Manjhi PK; Rai DK; Shyama ; Kumar A; Sarfaraz A
    J Pharm Pharm Sci; 2021; 24():343-350. PubMed ID: 34265236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2.
    Wamae CN
    Am J Trop Med Hyg; 2020 Jul; 103(1):10-11. PubMed ID: 32458795
    [No Abstract]   [Full Text] [Related]  

  • 17. Ivermectin: potential candidate for the treatment of Covid 19.
    Gupta D; Sahoo AK; Singh A
    Braz J Infect Dis; 2020; 24(4):369-371. PubMed ID: 32615072
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial.
    Mirahmadizadeh A; Semati A; Heiran A; Ebrahimi M; Hemmati A; Karimi M; Basir S; Zare M; Charlys da Costa A; Zeinali M; Sargolzaee M; Eilami O
    Respirology; 2022 Sep; 27(9):758-766. PubMed ID: 35738778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment on: 'Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients'.
    Garza-Santiago E; Ortiz-Hernández A; Kammar-García A; Mancilla-Galindo J
    Future Microbiol; 2022 Nov; 17():1277-1281. PubMed ID: 36111805
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients.
    Hazan S; Dave S; Gunaratne AW; Dolai S; Clancy RL; McCullough PA; Borody TJ
    Future Microbiol; 2022 Mar; 17():339-350. PubMed ID: 35135310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 50.